Stocks Health care GTBP

NASDAQ · Health care

GT Biopharma, Inc. (GTBP)

It posted a net loss of $4.8M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch GTBP in 60 seconds

Follow GTBP

Free, no password. An email when GTBP files with the SEC.

Key facts about GT Biopharma, Inc.

Net worth

GT Biopharma, Inc. has a market value (market cap) of $178.6M at the latest share price, and shareholders' equity of $3.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2020 revenue was $0, with a net loss of $28.3M.

Cash flow

In fiscal 2025 operations used $12.9M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

GT Biopharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What GT Biopharma, Inc. does

GT Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GTBP.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Dividends

It paid out $229K in cash dividends.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What GT Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 2, 2026
   Preliminary proxy statement PRE 14A
2. September 25, 2026
   Other event 8-K
3. September 21, 2026
   Material agreement8-KGT Biopharma amended its private placement agreement to add a new purchaser and increase the offering size to $7,750,000.
4. September 15, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. September 15, 2026
   Material agreement 8-K
6. September 3, 2026
   Shareholder rights changed 8-K
7. August 14, 2026
   Shareholder vote results 8-K
8. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.12 versus -$10.92.
9. July 2, 2026
   Proxy statement DEF 14A
10. June 18, 2026
    Preliminary proxy statement PRE 14A

Recent insider filings (Forms 3, 4 and 144): 8, the latest on September 8, 2025. Insider transactions on SEC

Insider trades

What the people running GT Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GTBP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Bristol Capital, LLC 4.76% (June 2, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GTBP

What does GT Biopharma, Inc. do?

GT Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as GTBP. Its shares trade on NASDAQ under the ticker GTBP.

What is GT Biopharma, Inc.'s net worth?

GT Biopharma, Inc. has a market value (market cap) of $178.6M at the latest share price, and shareholders' equity of $3.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is GT Biopharma, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $4.8M.

When did GT Biopharma, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from October 2, 2026.

When is GT Biopharma, Inc.'s next earnings report?

GT Biopharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare GTBP with

Compare GTBP with any company

Follow GTBP

Get an email when GT Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow GTBP

Free, no password. An email when GTBP files with the SEC.

Where the numbers come from

Financial figures are the values GT Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.